The chemical class γ1-Syntrophin inhibitors, also known as SNTG1 inhibitors, encompasses a range of compounds that impact the function of the protein Syntrophin gamma 1 indirectly by targeting the cellular pathways and processes it is involved in. These inhibitors interface with various biological systems to modulate the activity of SNTG1 without directly binding to the protein itself. For instance, some chemicals in this class are known to disrupt the stability and integrity of the dystrophin-associated protein complex (DAPC), a structure with which SNTG1 interacts. They achieve this by altering the ionic balance across the cell membrane or by affecting the cytoskeletal components that provide the structural framework necessary for the proper localization and functioning of SNTG1 within the DAPC. The changes in these fundamental cellular processes can modulate the function of SNTG1, particularly in muscle cells, where it plays a crucial role.
In addition to affecting the cytoarchitecture, members of this class can influence intracellular signaling cascades that SNTG1 is a part of. Some compounds act as antagonists to enzymes or ion channels, changing the flow of calcium and other ions, which can disrupt signal transduction processes that rely on these ions. Others interact with the synthesis or degradation pathways of second messengers like cAMP or cGMP, leading to an accumulation or depletion of these molecules, which then affects the downstream signaling pathways that SNTG1 is involved in. Furthermore, certain inhibitors target the regulation of actin dynamics or microtubule stability, processes that are essential for maintaining cell shape and facilitating intracellular transport. By altering these processes, the inhibitors can impact the mechanical stability and spatial arrangement of protein complexes, including those associated with SNTG1. These diverse modes of action illustrate the complex nature of SNTG1 inhibitors, which operate through indirect mechanisms to modulate the function of SNTG1 in cellular systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
By inhibiting Na⁺/K⁺-ATPase, Ouabain disrupts ionic homeostasis and membrane potential, which could impair DAPC stabilization where SNTG1 is a component, potentially leading to changes in muscle cell signaling and contraction. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
This compound disrupts the Golgi apparatus and protein trafficking, potentially altering the cellular distribution and membrane localization of SNTG1, impacting its ability to participate in cell signaling. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
By sequestering actin monomers, Latrunculin A prevents the polymerization of actin filaments, which could affect the cytoskeletal framework that supports SNTG1's interactions within the DAPC. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, inhibiting microtubule polymerization, which could disrupt intracellular transport systems and the cytoskeletal organization critical for SNTG1's normal function. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
As a calmodulin antagonist, W-7 Hydrochloride can impair calcium-mediated signal transduction pathways, potentially influencing SNTG1-associated calcium-dependent processes. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 inhibits myosin light chain kinase, potentially affecting muscle contraction and cellular movement, which could indirectly impact SNTG1's role in muscle cells. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
This L-type calcium channel blocker can change calcium ion influx, potentially affecting calcium-dependent pathways and thereby influencing SNTG1's function in such signaling cascades. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
By increasing cAMP levels, Forskolin can enhance or alter cAMP-dependent signaling pathways, which could affect SNTG1's interactions with signaling molecules that are regulated by cAMP levels. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
This ROCK inhibitor can modify actin cytoskeleton dynamics, which could affect the structural stability and localization of DAPC components, including SNTG1. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
By inhibiting protein kinase C, Gö 6983 can affect downstream signaling pathways, potentially altering SNTG1's role in signal transduction and protein interactions. | ||||||